trending Market Intelligence /marketintelligence/en/news-insights/trending/sTQVzEqt41hUe7DUmA_W1w2 content esgSubNav
In This List

Pfizer's breast cancer drug shows extended survival in phase 3 trial

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Pfizer's breast cancer drug shows extended survival in phase 3 trial

Pfizer Inc.'s phase 3 trial of talazoparib to treat breast cancer showed superior progression-free survival compared to standard chemotherapy.

In the EMBRACA phase 3 trial, talazoparib was given to one group of patients with germline, or inherited BRCA1/2-positive locally advanced and metastatic breast cancer, while the other group was treated with chemotherapy.

The drug extended life while keeping the disease at bay for a median of 8.6 months, representing a 46% reduction in the risk of disease progression, while progression-free survival for those given chemotherapy was 5.6 months.

About 62.6% of patients treated with talazoparib achieved a complete or partial response, compared to 27.2% for those on chemotherapy.

The results also showed that progression-free survival was consistent across prespecified subgroups, which included hormone receptor status, triple negative or hormone receptor-positive, BRCA mutation (1 or 2), prior chemotherapy and history of central nervous system metastases.

The incidence of serious adverse events was 31.8% in the talazoparib arm and 29.4% in the chemotherapy arm. About 7.7% of patients who received the medicine discontinued treatment due to adverse events.

Pfizer said talazoparib showed promising activity in patients with germline BRCA and metastatic breast cancer in another phase 2 trial, ABRAZO.

These patients had been previously treated with platinum-based chemotherapy or were heavily pretreated with at least three prior lines of non-platinum-based chemotherapy.